ZURA Stock Overview
A clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Zura Bio Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.25 |
| 52 Week High | US$13.00 |
| 52 Week Low | US$2.00 |
| Beta | 0.14 |
| 1 Month Change | 13.64% |
| 3 Month Change | 47.89% |
| 1 Year Change | -24.68% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -45.88% |
Recent News & Updates
Shareholder Returns
| ZURA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.4% | -0.4% | -0.6% |
| 1Y | -24.7% | 5.5% | 22.2% |
Return vs Industry: ZURA underperformed the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: ZURA underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| ZURA volatility | |
|---|---|
| ZURA Average Weekly Movement | 17.0% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ZURA's share price has been volatile over the past 3 months.
Volatility Over Time: ZURA's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 15 | Rob Lisicki | zurabio.com |
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Zura Bio Limited Fundamentals Summary
| ZURA fundamental statistics | |
|---|---|
| Market cap | US$327.21m |
| Earnings (TTM) | -US$60.18m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.4x
P/E RatioIs ZURA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZURA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$60.18m |
| Earnings | -US$60.18m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.97 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ZURA perform over the long term?
See historical performance and comparison